These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16594636)

  • 1. Role of monoamine transporters in mediating psychostimulant effects.
    Riddle EL; Fleckenstein AE; Hanson GR
    AAPS J; 2005 Dec; 7(4):E847-51. PubMed ID: 16594636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
    Fleckenstein AE; Volz TJ; Hanson GR
    Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):133-8. PubMed ID: 18662707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants.
    Jayanthi LD; Ramamoorthy S
    AAPS J; 2005 Oct; 7(3):E728-38. PubMed ID: 16353949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of psychostimulants on vesicular monoamine transporter function.
    Fleckenstein AE; Hanson GR
    Eur J Pharmacol; 2003 Oct; 479(1-3):283-9. PubMed ID: 14612158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.
    German CL; Baladi MG; McFadden LM; Hanson GR; Fleckenstein AE
    Pharmacol Rev; 2015 Oct; 67(4):1005-24. PubMed ID: 26408528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems.
    Ji J; Bourque M; Di Paolo T; Dluzen DE
    Biochem Pharmacol; 2009 Dec; 78(11):1401-11. PubMed ID: 19615345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine transporter as a target molecule for psychostimulants.
    Sora I; Li B; Fumushima S; Fukui A; Arime Y; Kasahara Y; Tomita H; Ikeda K
    Int Rev Neurobiol; 2009; 85():29-33. PubMed ID: 19607959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine transporters and psychostimulant addiction.
    Howell LL; Kimmel HL
    Biochem Pharmacol; 2008 Jan; 75(1):196-217. PubMed ID: 17825265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion increases striatal vesicular monoamine transport.
    Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
    Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the mechanism of action of amphetamines.
    Fleckenstein AE; Volz TJ; Riddle EL; Gibb JW; Hanson GR
    Annu Rev Pharmacol Toxicol; 2007; 47():681-98. PubMed ID: 17209801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.
    Riddle EL; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2007 Sep; 571(1):25-8. PubMed ID: 17618619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of monoamine transporter substrates.
    Rothman RB; Baumann MH
    Curr Top Med Chem; 2006; 6(17):1845-59. PubMed ID: 17017961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles.
    Schwartz K; Weizman A; Rehavi M
    J Neural Transm (Vienna); 2006 Sep; 113(9):1347-52. PubMed ID: 16362637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.
    Tucker KR; Block ER; Levitan ES
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4485-94. PubMed ID: 26216995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
    Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
    Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.
    Hanson GR; Sandoval V; Riddle E; Fleckenstein AE
    Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Amphetamines.
    Reith MEA; Gnegy ME
    Handb Exp Pharmacol; 2020; 258():265-297. PubMed ID: 31286212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
    Pifl C; Reither H; Hornykiewicz O
    Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.